Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Revenue	$ 18,394	$ 43,997	$ 0
Cost of goods sold:
Cost of goods sold	5,820	34,548	0
Gross margin	12,574	9,449	0
Operating expenses:
Research and development	28,268	9,527	24,090
General and administrative	9,388	18,198	7,143
Total operating expenses	37,656	27,725	31,233
Loss from operations	(25,082)	(18,276)	(31,233)
Other income (loss):
Interest income	467	2,456	564
Gain from Janssen Transaction	0	0	750,000
Other income (loss)	(132)	(503)	10
Foreign exchange gain (loss)	(711)	3,496	(888)
Total other income (loss)	(376)	5,449	749,686
Income before income taxes	(25,458)	(12,827)	718,453
Benefit (Provision) for income taxes	8,044	1,606	(49,824)
Net income (loss)	$ (17,414)	$ (11,221)	$ 668,629
Net income (loss) per share—basic (in dollars per share)	$ (0.58)	$ (0.36)	$ 17.17
Shares used to compute basic net income (loss) per share (in shares)	30,043,380	30,823,458	38,945,468
Net income (loss) per share—diluted (in dollars per share)	$ (0.58)	$ (0.36)	$ 14.44
Shares used to compute diluted net income (loss) per share (in shares)	30,043,380	30,823,458	46,319,457
Manufacturing Revenue [Member]
Revenue:
Revenue	$ 18,000	$ 18,000	$ 0
Cost of goods sold:
Cost of goods sold	5,517	12,859	0
Clinical Trial Service Revenue [Member]
Revenue:
Revenue	394	25,975	0
Cost of goods sold:
Cost of goods sold	303	21,689	0
Product and Service, Other [Member]
Revenue:
Revenue	$ 0	$ 22	$ 0